Bernd Werle

1.1k total citations
24 papers, 938 citations indexed

About

Bernd Werle is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Bernd Werle has authored 24 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cancer Research, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Bernd Werle's work include Protease and Inhibitor Mechanisms (16 papers), Peptidase Inhibition and Analysis (7 papers) and Bone health and treatments (4 papers). Bernd Werle is often cited by papers focused on Protease and Inhibitor Mechanisms (16 papers), Peptidase Inhibition and Analysis (7 papers) and Bone health and treatments (4 papers). Bernd Werle collaborates with scholars based in Germany, Slovenia and United States. Bernd Werle's co-authors include Janko Kos, Tamara T. Lah, W. Ébert, Eberhard Spieß, Nils Brünner, Klaus Kayser, Vito Türk, Nina Cimerman, Magnus Abrahamson and W. Fiehn and has published in prestigious journals such as Cancer, British Journal of Cancer and Experimental Cell Research.

In The Last Decade

Bernd Werle

24 papers receiving 909 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernd Werle Germany 18 564 347 265 135 115 24 938
Michael J. Niedbala United States 14 377 0.7× 303 0.9× 262 1.0× 137 1.0× 93 0.8× 16 917
J.L. Millán United States 13 314 0.6× 501 1.4× 81 0.3× 177 1.3× 89 0.8× 18 1.1k
Osamu Hosono Japan 23 239 0.4× 491 1.4× 623 2.4× 116 0.9× 102 0.9× 70 1.4k
Hideo Maki Japan 10 196 0.3× 476 1.4× 182 0.7× 22 0.2× 71 0.6× 15 789
Jørgen K. Larsen Denmark 20 288 0.5× 430 1.2× 290 1.1× 67 0.5× 91 0.8× 57 1.2k
Vishwas Ganu United States 13 451 0.8× 442 1.3× 498 1.9× 195 1.4× 47 0.4× 28 1.1k
Kathleen Norris United States 17 309 0.5× 758 2.2× 117 0.4× 126 0.9× 176 1.5× 30 1.0k
Lisa Natkin United States 4 374 0.7× 278 0.8× 117 0.4× 34 0.3× 78 0.7× 4 855
Liubov Zaritskaya United States 14 240 0.4× 487 1.4× 310 1.2× 35 0.3× 72 0.6× 18 1.1k
Jennifer Westling United States 10 415 0.7× 363 1.0× 170 0.6× 186 1.4× 286 2.5× 10 1.1k

Countries citing papers authored by Bernd Werle

Since Specialization
Citations

This map shows the geographic impact of Bernd Werle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Werle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Werle more than expected).

Fields of papers citing papers by Bernd Werle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Werle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Werle. The network helps show where Bernd Werle may publish in the future.

Co-authorship network of co-authors of Bernd Werle

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Werle. A scholar is included among the top collaborators of Bernd Werle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Werle. Bernd Werle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Watts, M., et al.. (2017). Effect of Delayed Digital Hypothermia on Lamellar Inflammatory Signaling in the Oligofructose Laminitis Model. Journal of Veterinary Internal Medicine. 31(2). 575–581. 13 indexed citations
2.
Werle, Bernd, Tamara T. Lah, W. Ébert, et al.. (2006). Cystatins in non-small cell lung cancer: Tissue levels, localization and relation to prognosis. Oncology Reports. 16(4). 647–55. 38 indexed citations
3.
Kos, Janko, Aleš Premzl, Tomaž Langerholc, et al.. (2005). Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Experimental Cell Research. 306(1). 103–113. 106 indexed citations
4.
Werle, Bernd, Matthias Kotzsch, Tamara T. Lah, et al.. (2005). Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.. PubMed. 24(6). 4147–61. 53 indexed citations
5.
Kayser, Klaus, et al.. (2003). Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer.. PubMed. 23(3C). 2767–72. 32 indexed citations
6.
Werle, Bernd, Carl‐Michael Nathanson, María Bjarnadóttir, et al.. (2003). Cystatins C, E/M and F in Human Pleural Fluids of Patients with Neoplastic and Inflammatory Lung Disorders. Biological Chemistry. 384(2). 281–7. 39 indexed citations
7.
Werle, Bernd. (2002). Immunohistochemical analysis of cathepsin B and cathepsin S in tumors, parenchyma and regional lymph nodes of the lung. Radiology and Oncology. 36(2). 1 indexed citations
8.
Cimerman, Nina, Robert Kuhelj, Bernd Werle, et al.. (2001). Cathepsin B/Cystatin C Complex Levels in Sera from Patients with Lung and Colorectal Cancer. Biological Chemistry. 382(5). 805–10. 44 indexed citations
9.
Kos, Janko, Gregor Kopitar, Nina Cimerman, et al.. (2001). Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. British Journal of Cancer. 85(8). 1193–1200. 78 indexed citations
10.
11.
Werle, Bernd, Tamara T. Lah, Janko Kos, et al.. (2000). Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer. 89(11). 2282–2282. 2 indexed citations
12.
Schweiger, Ana, Bernd Werle, Tamara T. Lah, et al.. (2000). Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking. British Journal of Cancer. 82(4). 782–788. 48 indexed citations
13.
Werle, Bernd, Tamara T. Lah, Janko Kos, et al.. (2000). Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer. 89(11). 2282–2291. 33 indexed citations
14.
Werle, Bernd, Tamara T. Lah, Endre Kálmán, et al.. (1999). Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients. British Journal of Cancer. 81(3). 510–519. 44 indexed citations
15.
Werle, Bernd, et al.. (1999). Fluorometric Microassays for the Determination of Cathepsin L and Cathepsin S Activities in Tissue Extracts. Biological Chemistry. 380(9). 1109–1116. 30 indexed citations
16.
Werle, Bernd, Nataša Kopitar‐Jerala, Janko Kos, et al.. (1997). Expression of Cysteine Protease Inhibitors Stefin A, Stefin B, and Cystatin C in Human Lung Tumor Tissue. Advances in experimental medicine and biology. 421. 259–265. 49 indexed citations
17.
Werle, Bernd, et al.. (1997). Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. British Journal of Cancer. 75(8). 1137–1143. 30 indexed citations
18.
Werle, Bernd, et al.. (1996). Charge polymorphism in human lung cell pro-cathepsin B.. PubMed. 16(1). 49–53. 3 indexed citations
19.
Ébert, W., et al.. (1995). Prognostic value of increased lung tumor tissue cathepsin B. Lung Cancer. 12(1-2). 130–130. 42 indexed citations
20.
Werle, Bernd, et al.. (1994). IMBALANCE BETWEEN CATHEPSIN-B AND CYSTEINE PROTEINASE-INHIBITORS IS OF PROGNOSTIC-SIGNIFICANCE IN HUMAN LUNG-CANCER. International Journal of Oncology. 5(1). 77–85. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Niedbala Breakdown of academic impact, for papers by J.L. Millán Breakdown of academic impact, for papers by Osamu Hosono Breakdown of academic impact, for papers by Hideo Maki Breakdown of academic impact, for papers by Jørgen K. Larsen Breakdown of academic impact, for papers by Vishwas Ganu Breakdown of academic impact, for papers by Kathleen Norris Breakdown of academic impact, for papers by Lisa Natkin Breakdown of academic impact, for papers by Liubov Zaritskaya Breakdown of academic impact, for papers by Jennifer Westling
Rankless by CCL
2026